Deep Health AI India Ltd
Incorporated in 1993, Deep Diamond India Ltd is in the business of trading Diamond, Jewellery and Pharma products[1]
- Market Cap ₹ 24.8 Cr.
- Current Price ₹ 1.72
- High / Low ₹ 10.3 / 1.72
- Stock P/E 3.98
- Book Value ₹ 1.78
- Dividend Yield 5.81 %
- ROCE 5.28 %
- ROE 4.02 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.96 times its book value
- Company has delivered good profit growth of 98.3% CAGR over last 5 years
Cons
- The company has delivered a poor sales growth of 9.06% over past five years.
- Promoter holding is low: 0.03%
- Company has a low return on equity of 5.06% over last 3 years.
- Earnings include an other income of Rs.4.31 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.55 | 3.13 | 1.17 | 3.29 | 1.66 | 1.25 | 0.81 | 0.51 | 1.39 | 7.67 | 2.56 | 1.25 | 4.45 | |
| 2.69 | 3.04 | 1.40 | 3.38 | 1.94 | 1.54 | 1.11 | 0.74 | 1.38 | 6.03 | 2.80 | 0.80 | 0.92 | |
| Operating Profit | -0.14 | 0.09 | -0.23 | -0.09 | -0.28 | -0.29 | -0.30 | -0.23 | 0.01 | 1.64 | -0.24 | 0.45 | 3.53 |
| OPM % | -5.49% | 2.88% | -19.66% | -2.74% | -16.87% | -23.20% | -37.04% | -45.10% | 0.72% | 21.38% | -9.38% | 36.00% | 79.33% |
| 0.62 | 0.16 | 0.19 | 0.22 | 0.28 | 0.28 | 0.29 | 0.26 | 0.26 | 0.23 | 1.09 | 0.75 | 4.31 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.26 | 0.09 | 0.06 |
| Depreciation | 0.03 | 0.03 | 0.05 | 0.04 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 |
| Profit before tax | 0.45 | 0.22 | -0.09 | 0.09 | -0.02 | -0.03 | -0.03 | 0.01 | 0.27 | 1.73 | 0.58 | 1.10 | 7.78 |
| Tax % | 22.22% | 31.82% | -11.11% | 22.22% | 0.00% | 0.00% | 0.00% | 500.00% | 25.93% | 27.75% | 27.59% | 21.82% | |
| 0.35 | 0.15 | -0.07 | 0.07 | -0.02 | -0.02 | -0.03 | -0.05 | 0.20 | 1.26 | 0.42 | 0.86 | 6.23 | |
| EPS in Rs | 0.04 | 0.02 | -0.01 | 0.01 | -0.00 | -0.00 | -0.00 | -0.01 | 0.02 | 0.13 | 0.04 | 0.09 | 0.45 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -9% |
| 5 Years: | 9% |
| 3 Years: | -3% |
| TTM: | 77% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 98% |
| 3 Years: | 68% |
| TTM: | 1732% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 6% |
| 3 Years: | -44% |
| 1 Year: | -59% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 5% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.99 | 3.20 | 3.20 | 3.20 | 3.20 | 3.20 | 3.20 | 3.20 | 3.20 | 4.81 | 4.81 | 4.81 | 4.81 |
| Reserves | 4.01 | 4.43 | 4.36 | 4.44 | 4.45 | 4.38 | 4.30 | 4.28 | 4.48 | 9.92 | 15.62 | 17.54 | 20.92 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.86 | 1.66 | 0.61 | 0.36 | |
| 0.62 | 0.15 | 0.22 | 0.24 | 0.07 | 0.07 | 0.30 | 0.11 | 0.06 | 1.29 | 0.98 | 0.99 | 2.35 | |
| Total Liabilities | 7.62 | 7.78 | 7.78 | 7.88 | 7.72 | 7.65 | 7.80 | 7.59 | 7.74 | 19.88 | 23.07 | 23.95 | 28.44 |
| 0.45 | 0.40 | 0.36 | 0.32 | 0.30 | 0.29 | 0.27 | 0.00 | 0.00 | 4.47 | 4.46 | 4.45 | 0.01 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.04 | 0.13 | 0.10 | 0.16 | 0.17 | 0.25 | 0.19 | 0.26 | 0.20 | 0.00 | 3.56 | 5.59 | 12.00 |
| 7.13 | 7.25 | 7.32 | 7.40 | 7.25 | 7.11 | 7.34 | 7.33 | 7.54 | 15.41 | 15.05 | 13.91 | 16.43 | |
| Total Assets | 7.62 | 7.78 | 7.78 | 7.88 | 7.72 | 7.65 | 7.80 | 7.59 | 7.74 | 19.88 | 23.07 | 23.95 | 28.44 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.26 | -0.39 | -0.19 | 0.08 | -0.69 | -0.25 | -0.28 | -0.15 | 0.55 | 3.23 | -5.41 | 0.19 | |
| 0.51 | 0.06 | 0.23 | 0.18 | 0.29 | 0.13 | 0.30 | 0.27 | 0.29 | -4.03 | -2.25 | -0.23 | |
| -0.23 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.79 | 5.01 | 0.00 | |
| Net Cash Flow | 0.02 | 0.17 | 0.04 | 0.26 | -0.40 | -0.12 | 0.02 | 0.12 | 0.84 | 4.99 | -2.65 | -0.04 |
| Free Cash Flow | 0.21 | -0.39 | -0.19 | 0.08 | -0.69 | -0.26 | -0.28 | -0.08 | 0.55 | -1.25 | -5.41 | 0.19 |
| CFO/OP | 186% | -433% | 65% | -156% | 246% | 86% | 93% | 65% | 5,700% | 203% | 2,254% | 42% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 154.59 | 213.40 | 455.47 | 142.01 | 167.11 | 169.36 | 202.78 | 293.43 | 118.17 | 127.54 | 208.16 | 148.92 |
| Inventory Days | 889.05 | 446.78 | 1,621.71 | 400.81 | 877.67 | 1,120.30 | 1,942.92 | 3,432.97 | 1,207.61 | 86.55 | 264.73 | 1,241.00 |
| Days Payable | 0.00 | 0.00 | 69.30 | 19.28 | 0.00 | 0.00 | 0.00 | 0.00 | 11.65 | 84.11 | 236.65 | 1,630.33 |
| Cash Conversion Cycle | 1,043.64 | 660.19 | 2,007.88 | 523.53 | 1,044.78 | 1,289.66 | 2,145.70 | 3,726.40 | 1,314.12 | 129.99 | 236.24 | -240.41 |
| Working Capital Days | 918.94 | 798.80 | 2,130.73 | 735.55 | 886.11 | 1,138.80 | 1,662.78 | 2,784.02 | 947.95 | -60.91 | -27.09 | 40.88 |
| ROCE % | 2.31% | 3.01% | -1.18% | 1.18% | -0.26% | -0.39% | -0.40% | -0.40% | 3.30% | 14.24% | 4.03% | 5.28% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory Value INR Hundreds |
|
|||||||||||
| Permanent Employee Count Number |
||||||||||||
| Business Segment Focus - Pharmaceuticals Consultancy Binary (1=Active) |
||||||||||||
| Associate and Subsidiary Entities Count |
||||||||||||
| Manufacturing Facilities (Oasis Ceramics - Acquisition) Count |
||||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Restructuring
24h - Board approved filing to strike off wholly owned Microcure Biotech Pvt Ltd; FY24-25 turnover NIL; net worth Rs.2,00,000.
-
Board Meeting Outcome for Outcome Of Board Meeting Of The Company Held Today I.E. Wednesday, April 01, 2026.
24h - Board approved application to strike off wholly-owned Microcure Biotech Pvt Ltd; FY24-25 turnover NIL, net worth Rs.2,00,000.
-
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
29 Mar - Shareholders approved increase in authorized share capital and MOA alteration via postal ballot on March 28, 2026.
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 28 Mar
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 28 Mar
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
DDIL is engaged in the business of Rough & Polished Diamonds, sale, and trading of
diamond studded jewellery & Gold
Jewellery, and marketing of pharmaceutical goods and providing consultancy service
to the Pharmaceutical industry